Phaseline

Targets › LAMP1

LAMP1 (Lysosome-associated membrane glycoprotein 1): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Feb 2028.

Lysosomal membrane glycoprotein which plays an important role in lysosome biogenesis, lysosomal pH regulation, autophagy and cholesterol homeostasis. Acts as an important regulator of lysosomal lumen pH regulation by acting as a direct inhibitor of the proton channel TMEM175, facilitating lysosomal acidification for optimal hydrolase activity. (UniProt, P11279)

Open in Phaseline: the race on LAMP1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Immunomic TherapeuticsITI-5000
Self-amplifying RNA vaccine targeting HERV-K and CT83 fused with LAMP-1
HERVK, CT83, LAMP1Phase 1Triple Negative Breast Cancer (TNBC)Feb 2028

Conditions

Triple Negative Breast Cancer (TNBC) (1)

Modalities

mixed (1)

Companies

Immunomic Therapeutics (1)

Related targets

HERVK (1) CT83 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.